EMERALD Trial Design and Baseline Characteristics

The study enrolled 694 patients randomly assigned 1:1 to receive elacestrant or physician’s choice of standard therapy. Stratification factors included ESR1 mutational status, visceral metastases, and prior fulvestrant use. The primary end point was progression-free survival, with overall survival as a secondary end point. The patient population primarily consisted of those previously treated with CDK4/6 inhibitors and up to one prior chemotherapy line.